Company intelligence / Profile preview

EDAP TMS

Lyon, Auvergne-Rhône-Alpes, Franceedap-tms.com ↗

Ownership: Private
Employees: ~200
Development stage: Other

Overview

EDAP TMS has commercialized two generations of HIFU devices for prostate cancer—Ablatherm® Robotic HIFU and Focal One®—both FDA approved. The company also markets the ExactVu™ micro-ultrasound system for targeted prostate biopsies and the Sonolith® i-move lithotripter for stone management. Their solutions are used globally in hospitals and clinics

Therapeutic areas: NephrologyOncology
Modalities: Device
Industry: Medical Imaging

Partnerships

Avenda Health – partnership to launch AI-assisted focal therapy planning platform integrating deep learning with Focal One device

Beyond the preview

Go deeper on EDAP TMS.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EDAP TMS.

Explore the full profile